FairJourney Biologics
João Paulo Alpendre has a diverse work experience across various industries. João Paulo is currently the Head of the Logistics Division and New Ventures Unit at FairJourney Biologics since 2022. Prior to that, they were the Founder and Managing Partner at Companhia de Investimentos e Serviços Furnas Atlântico since 2015.
João Paulo has also held roles such as Vogal do Conselho Fiscal at Atrium - Sociedade Financeira de Corretagem, SA from 2017 to 2022 and at H Capital - SCR, SA from 2015 to 2022. Additionally, they served as the Executive Director at Iberfar - Indústria Farmacêutica, SA from 2018 to 2022 and as the Director-General Hospital at Grupo Luz Saúde from 2016 to 2018.
Earlier in their career, João Paulo Alpendre held positions such as Non-Executive Board Member at ETI - Empordef Tecnologias de Informação from 2015 to 2017, Group CFO at EIP Electricidade Industrial Portuguesa from 2013 to 2014, and Executive Director, Partner, CFO at ES Ventures, SCR, SA from 2000 to 2013.
João Paulo also had a brief experience as the Chairman of the Board at Instituto de Gestão Financeira e Patrimonial da Justiça in 2004.
João Paulo Alpendre obtained a Bachelor of Science (BSc) degree in Economics from Universidade Católica Portuguesa. João Paulo attended the university from 1981 to 1987.
This person is not in any offices
FairJourney Biologics
FairJourney Biologics is a privately established company with an outstanding track record of biotech and biopharmaceutical partners (Merus, argenX, BMS, Bayer, among others), offering a range of assets and services on antibody discovery, engineering, production, characterization up to cell line development stages. Our naïve and immune libraries from humans, rodents and llama, together with our know-how and internal technological development allow us to contribute to the pipeline of our partners on complex targets, leading to 14 known antibodies in the clinic. More recently, FairJourney Biologics has been joined by specialists in the field such as Tariq Ghayur (formerly Abbvie) and Rene Hoet (formerly Bayer), creating a panel of available scientists as service to support complex antibody projects. From target validation up to cell line development and pre-CMC reporting, FairJourney Biologics is a one stop shop leader in antibody services. As of 2022, the company has a headcount of above 200 staff members and a track record of more than 800 projects on a variety of areas.